Search
Search Results
##search.searchResults.foundPlural##
-
ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS
1740PDF: 850HTML: 964cover letter: 301 -
CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.
3356PDF: 933HTML: 1549Fig.1 CHL-R paper: 241Fig 2 CHL-R paper: 265 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4928PDF: 1860HTML: 2866Untitled: 252 -
Guest Editor: G. Castaman AGING WITH HEMOPHILIA: THE CHALLENGE OF APPROPRIATE DRUG PRESCRIPTION Hemophilia and aging
2997PDF: 1494HTML: 321 -
WHAT UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA TAUGHT US ABOUT TRANSPLANT IMMUNOGENETICS.
3260PDF: 1175HTML: 1685Untitled: 203Untitled: 191Untitled: 190 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3327PDF: 968HTML: 3209 -
ANTIFUNGAL THERAPY IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
4870PDF: 1603HTML: 2267Untitled: 252Untitled: 266Untitled: 286Untitled: 236Untitled: 253 -
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3779PDF: 1341HTML: 2168Fig.1: 238Fig. 2: 232 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4482PDF: 1804HTML: 1124 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1952PDF: 1205HTML: 337 -
Glucocorticoids and antivirals for HBV reactivation in onco-hematologic patients
1028PDF: 588HTML: 2224Cover Letter: 216 -
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS. Anti-CMV immunoglobulins for CMV treatment
2649PDF: 1223HTML: 283 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3798PDF: 936HTML: 6876 -
MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA
765PDF: 482HTML: 6282 -
Massive pulmonary embolism at the onset of acute promyelocytic leukemia
3607PDF: 920HTML: 1689figure 1: 189Untitled: 212 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2509PDF: 1640HTML: 706 -
SHORT HISTORY OF MALARIA AND ITS ERADICATION IN ITALY
5103PDF: 1997HTML: 11450Fig 1: 255Fig 2: 210Fig 3: 335Fig 4: 213Fig 5: 218Fig 6: 209Fig 7: 228Fig 8: 208 -
IMPORTANCE OF HYPERBILURUBINEMIA IN DIFFERENTIATION OF PRIMARY AND SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN PEDIATRIC CASES
1848PDF: 972HTML: 1198Untitled: 184Untitled: 203Untitled: 191Untitled: 186 -
THALASSEMIA AND VENOUS THROMBOEMBOLISM
3033PDF: 1144HTML: 4676 -
AGING WITH THALASSEMIA AND SICKLE CELL DISEASE: A GERONTOLOGICAL MODEL OF ACCELERATED MULTIMORBIDITY AND FUNCTION-CENTERED CARE BEYOND MIDLIFE Thalassemia and Sickle Cell Diseases: Effect of Aging
522PDF: 572Suppl. Files: 68HTML: 159 -
Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis.
1833PDF: 583HTML: 16995Figure 4: 192Figure 3: 162Figure 2: 168Figure 1: 204 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
4371Suppl. Files: 1221PDF: 1131Html: 268 -
SIMPLE PERIPHERAL BLOOD SMEAR FINDINGS OF COVID-19 PATIENTS PROVIDE INFORMATION ABOUT THE SEVERITY OF THE DISEASE AND THE DURATION OF HOSPITAL STAY. Peripheral blood smear and COVID-19 severity.
3535PDF: 1246HTML: 507 -
WHAT ARE FUNGAL INFECTIONS?
4336PDF: 2475HTML: 27699de Pauw: 263 -
-
APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA
1712PDF: 672HTML: 2444 -
HEPATITIS B AND C IN HEMATOPOIETIC STEM CELL TRANSPLANT
1028PDF: 557HTML: 741







